Bowers P - Search Results

1

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.

Leyland-Jones B, Bondarenko I, Nemsadze G, Smirnov V, Litvin I, Kokhreidze I, Abshilava L, Janjalia M, Li R, Lakshmaiah KC, Samkharadze B, Tarasova O, Mohapatra RK, Sparyk Y, Polenkov S, Vladimirov V, Xiu L, Zhu E, Kimelblatt B, Deprince K, Safonov I, Bowers P, Vercammen E. Leyland-Jones B, et al. Among authors: bowers p. J Clin Oncol. 2016 Apr 10;34(11):1197-207. doi: 10.1200/JCO.2015.63.5649. Epub 2016 Feb 8. J Clin Oncol. 2016. PMID: 26858335 Clinical Trial.

2

A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.

Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P. Pergola PE, et al. Among authors: bowers p. Clin J Am Soc Nephrol. 2009 Nov;4(11):1731-40. doi: 10.2215/CJN.03470509. Epub 2009 Sep 17. Clin J Am Soc Nephrol. 2009. PMID: 19808215 Free PMC article. Clinical Trial.

3

A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.

Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P. Pergola PE, et al. Among authors: bowers p. Clin J Am Soc Nephrol. 2010 Apr;5(4):598-606. doi: 10.2215/CJN.06770909. Epub 2010 Feb 25. Clin J Am Soc Nephrol. 2010. PMID: 20185602 Free PMC article. Clinical Trial.

4

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH; PROACTIVE Study Group. Pockros PJ, et al. Hepatology. 2004 Dec;40(6):1450-8. doi: 10.1002/hep.20482. Hepatology. 2004. PMID: 15565613 Clinical Trial.

5

Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients.

Saag MS, Bowers P, Leitz GJ, Levine AM; Community HIV Anemia Management Protocol Sites (CHAMPS) Study Group. Saag MS, et al. Among authors: bowers p. AIDS Res Hum Retroviruses. 2004 Oct;20(10):1037-45. doi: 10.1089/aid.2004.20.1037. AIDS Res Hum Retroviruses. 2004. PMID: 15587490 Clinical Trial.

6

Epoetin alfa. Clinical evolution of a pleiotropic cytokine.

Henry DH, Bowers P, Romano MT, Provenzano R. Henry DH, et al. Among authors: bowers p. Arch Intern Med. 2004 Feb 9;164(3):262-76. doi: 10.1001/archinte.164.3.262. Arch Intern Med. 2004. PMID: 14769622 Review.

7

Efficacy and safety of epoetin alfa in critically ill patients.

Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ; EPO Critical Care Trials Group. Corwin HL, et al. Among authors: bowers pj. N Engl J Med. 2007 Sep 6;357(10):965-76. doi: 10.1056/NEJMoa071533. N Engl J Med. 2007. PMID: 17804841 Free article. Clinical Trial.

8

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ; Proactive Study Group. Afdhal NH, et al. Gastroenterology. 2004 May;126(5):1302-11. doi: 10.1053/j.gastro.2004.01.027. Gastroenterology. 2004. PMID: 15131791 Clinical Trial.

9

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.

Dieterich DT, Wasserman R, Bräu N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS. Dieterich DT, et al. Am J Gastroenterol. 2003 Nov;98(11):2491-9. doi: 10.1111/j.1572-0241.2003.08700.x. Am J Gastroenterol. 2003. PMID: 14638354 Clinical Trial.

10

Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients.

Grossman HA, Goon B, Bowers P, Leitz G; 010 Study Group. Grossman HA, et al. Among authors: bowers p. J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):368-78. doi: 10.1097/00126334-200312010-00003. J Acquir Immune Defic Syndr. 2003. PMID: 14615654 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

150 results

Search Page